CONSHOHOCKEN, PA--(Marketwire - September 30, 2011) - NuPathe Inc. (NASDAQ: PATH) today announces that Jane Hollingsworth, chief executive officer, will present at the Safeguard Scientifics Investor Day 2011 at The Yale Club of New York City on Tuesday, October 4, 2011.
If you are interested in attending or for additional information, please visit Safeguard’s microsite at www.safeguard.com/investorday2011.
A link to the webcast of the presentation will also be available via the “Investor Relations” page of the NuPathe website, www.nupathe.com.
About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe’s lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In addition to NP101, NuPathe has two additional proprietary product candidates: NP201 for the continuous symptomatic treatment of Parkinson’s disease, which the company plans to partner, and NP202 in preclinical development for the long-term treatment of schizophrenia and bipolar disorder.
Contact Information:
John Woolford
(443) 213-0506
john.woolford@westwicke.com
Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130
